FDA Aggressively Looking for Data Integrity Problems in Inspections
This article was originally published in The Gold Sheet
FDA inspectors using a new forensic approach to inspections in responding to a rash of data integrity problems found in pharmaceutical manufacturing facilities. Attorneys advise firms to pay careful attention to their adverse event reports and field alert reports as data integrity breaches can be found there too.
You may also be interested in...
US FDA warns that Health Pharma USA was shipping product before its quality unit could review and test it.
Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.
Launching desktop assessments to ease the inspectional workload of regulators and forging stronger relationships with India and China are two key priorities for the international inspectorate group this year.